Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × Trastuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 20 Stomach Neoplasms 6 Neoplasms 4 Neoplasm Metastasis 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Adenocarcinoma Of Esophagus 3 Triple Negative Breast Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 HER2-positive Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Solid Tumors 1 Resectable HER2-positive Breast Cancer 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Meningeal Neoplasms 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Gastric Cancer 1 HER2-positive Early Breast Cancer 1 Gastroesophageal Adenocarcinoma 1 Gallbladder Neoplasms 1 Endometrial Neoplasms 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡